Evidence map›Paper›PMID 41228297›Full record

ArticleCancers2025

Characteristics of Peripheral Blood Lymphocyte Populations in Patients with Locally Advanced Unresectable Non-Small Cell Lung Cancer.

Lyudmila Grivtsova, Anastasia Glukhareva, Anzhelika Melnikova, Tatiana Mushkarina, Grigoriy Afonin, Anna Efremova, Sergey Ivanov, Dmitry Goldshtein, Andrey Kaprin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lyudmila GrivtsovaA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.
Anastasia GlukharevaA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.
Anzhelika MelnikovaA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.
Tatiana MushkarinaA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.ORCID 0000-0002-1266-1792
Grigoriy AfoninA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.
Anna EfremovaResearch Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia.
Sergey IvanovA. Tsyb Medical Radiological Research Center (MRRC)-The Branch of the FSBI "National Medical Research Radiological Centre" (NMRRC) of the Ministry of Health of the Russian Federation, 4 Koroleva St., Obninsk 249036, Russia.
Dmitry GoldshteinResearch Centre for Medical Genetics, 1 Moskvorechye St., Moscow 115522, Russia.
Andrey KaprinResearch Institute of Molecular and Cellular Medicine and Biochemistry Department, Peoples' Friendship University of Russia, 6 Miklukho-Maklaya St., Moscow 117198, Russia.

Funding

Russian Science Foundation 25-15-00376, "Study on the cytotoxic mechanism of exosomes derived from CAR-NK-92 cells, including with RAB27a protein overexpression"
6 · The paper itself

Abstract

backgroundThe main type of treatment of unresectable NSCLC is chemoradiotherapy, which has a relatively high toxicity. One option allowing to reduce the toxicity of this approach may be immunocorrective therapy. The appointment of this type of treatment should be warranted in terms of patient's immune system response. This confirms the importance of verifying systemic immune disorders in primary patients with NSCLC. GOAL: To assess the features of the population of immune cells in peripheral blood in patients with stage IIIB, IIIC primary NSCLC and to identify any signs of secondary immunodeficiency in this cohort.

methodsWe analyzed the frequencies of circulating T cells (CD3+, CD4+, CD8+), B-cells (CD19+), NK-cells (CD3-CD16+CD56+ cell), and NKT-cells (CD3+CD56+ cells) within CD45+ cells (lymphocytes) in 80 patients with stage IIIB-IIIC NSCLC, and in 40 healthy controls using eight-color flow cytometry.

resultsIn patients with stages IIIB-IIIC primary NSCLC, changes within immunocompetent blood cells were found. Moreover, it was unveiled that quantitative changes affected all major immunocompetent cells. A decrease in the proportion of CD4+ T cells and B lymphocytes and an increase in the number of NK and NKT cells were found. Also, an increase in the number of double-positive CD4+CD8+ T cells was revealed, as well as a significant increase in the proportion of B1a (CD5+CD19+) cells among B lymphocytes (qualitative disorders).

conclusionThe revealed multidirectional changes among immunocompetent peripheral blood cells in patients with locally advanced NSCLC (stages IIIB-IIIC) can be beyond doubt considered as signs of systemic immune disorders in this cohort (secondary immunodeficiency).

Indexed as

flow cytometrynon-small cell lung carcinoma (NSCLC)peripheral blood lymphocyte subpopulations

Identifiers

PMID41228297
PMCPMC12607589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.